MERGER AND SUBSEQUENT SALE (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Sep. 30, 2019	Nov. 30, 2018	Dec. 31, 2019	Dec. 31, 2018
Bad debt expense			$ 356,851
Gain on disposition of subsidiary			$ 316,985
Common stock, par value			$ 0.001	$ 0.001
Issuance of stock options in Merger				$ 599,998
Maximum [Member]
Ownership percentage		4.99%
Preferred Stock Series C [Member]
Shares issued for acquisation of shares	36,000
Issuance of stock options in Merger
EllisLab, Inc [Member]
Payment for acquisation of shares	$ 10,000		$ 10,000
Common stock, par value		$ 0.001
Total		$ 4,945,864	$ 4,945,864
Preferred Stock, shares issued under merger		36,000
Ownership interest		100.00%
Share price		$ 100
Preferred stock shares issued, value		$ 4,345,866
Jones [Member] | Nonstatutory Stock Option Agreement Member | Stock Options [Member]
Common stock shares reserved for future issuance		444,445
Exercise price		0.005
Description for stock options surrendered by related party		Company issued to Jones an option to purchase 444,445 shares of the Common stock of the Company, at an exercise price of $1.13 (the “Option”), in exchange for his surrender of an option to purchase 10% of the shares of outstanding common stock of EllisLab, Inc.
Issuance of stock options in Merger		$ 599,998
Impairment expense		$ 4,934,429
Description for the exercise period		The Option vested but may not be exercised for two years from the date of the Merger.